Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $2.47 USD
Change Today -0.06 / -2.37%
Volume 1.0M
VVUS On Other Exchanges
As of 8:10 PM 05/26/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

351 East Evelyn Avenue

Mountain View, CA 94041

United States

Phone: 650-934-5200


VIVUS, Inc., a biopharmaceutical company, develops and commercializes therapies to address unmet needs in obesity, sleep apnea, diabetes, and sexual health in the United States and the European Union. Strategy The company’s strategy include establishing medical obesity treatment as a widely accepted and reimbursed, chronic category supported by treatment guidelines; expanding the use of Qsymia through targeted physician, payor and patient education; increased third-party payor coverage, continuing to lower out-of-pocket costs for patients with discount programs, and changes in public policy to obtain coverage for obesity under Medicare Part D; successfully expanding the certified retail pharmacy distribution channel for Qsymia in the United States; creating a pathway for centralized approval of Qsiva in Europe; finding the right partner for expanded Qsymia commercial promotion to a broader primary care physician audience; and managing its alliances with Auxilium Pharmaceuticals, Inc. (Auxilium), Menarini Group, and Sanofi, to help ensure the commercial success of avanafil. Products and Development Programs Qsymia for the treatment of Obesity The company’s drug Qsymia (phentermine and topiramate extended-release) was approved by the U.S. Food and Drug Administration (FDA) in 2012, as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of 30 or greater (obese), or 27 or greater (overweight) in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus or high cholesterol (dyslipidemia). Qsymia in development for Obstructive Sleep Apnea (OSA) OSA, is a chronic and potentially serious sleep disorder in which breathing is abnormally shallow, or hypopnea, or stops altogether, or apnea, for at approximately 10 seconds. In 2010, the company announced positive results from a Phase 2 study evaluating the safety and efficacy of Qsymia for the treatment of moderate to severe OSA. Qsymia in development for Diabetes The approved oral medications for type 2 diabetes include insulin releasers, such as glyburide, insulin sensitizers, such as Actos and Avandia, inhibitors of glucose production by the liver, such as metformin, DPP-IV inhibitors like Januvia, as well as Precose and Glyset, which slow the uptake of glucose from the intestine. Approved injectable medications for type 2 diabetes treatment include glucagon-like peptide-1, or GLP-1, analogs, such as liraglutide, marketed under the brand name Victoza, developed by Novo Nordisk A/S and exenatide, marketed under the brand name Byetta, and a long-acting version of exenatide marketed under the brand name Bydureon, developed by Amylin Pharmaceuticals and Eli Lilly and Company. The company also studied the effect of Qsymia on well-controlled diabetics as part of its Phase 3 obesity study, CONQUER, (OB-303). Qsymia in development for Other Indications The company’s Qsymia may be helpful in treating other obesity-related diseases, including nonalcoholic steatohepatitis, or NASH, or its precursor, nonalcoholic fatty liver disease, or NAFLD, also known as fatty liver disease. It is contemplating whether to pursue these other indications. STENDRA for the treatment of Erectile Dysfunction (ED) The company’s drug STENDRA, or avanafil, is an oral phosphodiesterase type 5, or PDE5, inhibitor that it has licensed from Mitsubishi Tanabe Pharma Corporation, or MTPC. STENDRA was approved by the FDA in 2012, for the treatment of ED in the United States. In 2013, the company entered into an agreement with Menarini Group, through its subsidiary Berlin-Chemie AG, under which Menarini Group received an exclusive license to commercialize and promote SPEDRA for the treatment of ED in approximately 40 European countries, including the EU, plus Australia and New Zealand. Other Programs The company has licensed and intends to continue to license from third parties the rights to other investigational drug candidates to treat various diseases and medical conditions. Collaboration Agreements In 2013, the company entered

Page 12Next Page

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VVUS:US $2.47 USD -0.06

VVUS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Arena Pharmaceuticals Inc $4.10 USD -0.09
GlaxoSmithKline Consumer Healthcare Ltd 6,414 INR +66.00
Novo Nordisk A/S kr390.50 DKK +0.40
Orexigen Therapeutics Inc $4.95 USD -0.065
Takeda Pharmaceutical Co Ltd ¥5,953 JPY -58.00
View Industry Companies

Industry Analysis


Industry Average

Valuation VVUS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.4x
Price/Book 3.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VIVUS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at